Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    RENAL CANCER E7080
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Lenvatinib;   Drug: Everolimus;   Drug: Lenvatinib plus Everolimus
2 Recruiting A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Drug: Lenvatinib;   Drug: Nexavar

Indicates status has not been verified in more than two years